Litigation Details for Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2021)

✉ Email this page to a colleague

Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2021)

Docket	1:21-cv-01043	Date Filed	2021-07-16
Court	District Court, D. Delaware	Date Terminated	2023-03-29
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137; 10,857,148; 10,874,648; 10,906,902; 10,906,903; 10,912,771; 10,919,892; 10,940,141; 10,952,997
Link to Docket	External link to docket

Small Molecule Drugs cited in Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .

Details for Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2021)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2021-07-16				External link to document
2021-07-16	1	Complaint	civil action for patent infringement of U.S. Patent Nos. 10,065,952 (“the ’952 patent”), 10,844,058 (“…(“the ’058 patent”), 10,851,103 (“the ’103 patent”), 10,851,104 (“the ’104 patent”), 10,857,137 (“the…the ’137 patent”), 10,857,148 (“the ’148 patent”), 10,874,648 (“the ’648 patent”), 10,906,902 (“the ’902…’902 patent”), 10,906,903 (“the ’903 patent”), 10,912,771 (“the ’771 patent”), 10,919,892 (“the ’892 …892 patent”), 10,940,141 (“the ’141 patent”) and 10,952,997 (“the ’997 patent”) (collectively, “patents-in-suit	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation summary and analysis for: Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2021)

Last updated: July 16, 2026

Neurocrine Biosciences v. Teva 1:21-cv-01043: Litigation Summary, Patent Claims, and Generic Entry Risk

Executive summary: Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc., 1:21-cv-01043 (D.N.J.) is a US patent infringement dispute tied to Teva’s proposed generic launch. The case is docketed as a Hatch-Waxman-style infringement action (typically anchored to an Orange Book listing and an Abbreviated New Drug Application). This matter impacts timeline and risk around generic availability for the relevant Neurocrine product by contesting one or more Orange Book-listed patents (device/system or small-molecule patents are both possible depending on the underlying NDA/ANDA listing).

What matters for business: the case’s strength hinges on (1) which listed patents Neurocrine asserted, (2) claim construction outcomes, (3) any stipulations/partial dismissals, and (4) whether a settlement entered that carves out market entry dates for Teva.

No case-specific asserted-patent list, claim chart details, procedural milestones, or settlement terms are provided in the prompt. Under the constraints, a complete and accurate litigation summary cannot be produced without those docket facts.